Medical Affairs Role in Supporting Continuing Medical Education (CME) Programs

STUDY OVERVIEW

Still, new compliance and transparency rules and regulations have tempered the sponsorship of some medical education programs by pharma companies.

This benchmark study was conducted to inform those that lead Medical Education functions on the approval process and the approaches to measuring performance of such programs.

KEY TOPICS

• CME Scope, Focus and Standardization
• Internal Process to Approve CME Proposals
• When and to whom CME information is shared
• Measuring Effectiveness of CME Proposals
• Systems Used to Manage CME Proposals
• Budget Spent on Medical Education

KEY METRICS

• Geographic region that you support with medical education function
• Do you have SOP or policy regarding CME in your company
• Describe your SOP or policy
• Do you have an internal faculty or team that approves CME proposals? Who approves in your organization?
• What commercial colleagues do you provide updates on CME proposals prior to approval
• Why do you not provide updates prior to approvals
• What commercial colleagues do y9ou provide updates on CME proposals after approval
• Do you measure the effectiveness of your CME proposals? How do you measure?
• What percentage of medical affairs budget is spent annually on CME
• What will be critical issues for medical education in the next 24-36 months

SAMPLE KEY FINDINGS

• At more than 70% of companies, internal faculty or a team consider CME proposals submitted by providers. For those internal teams, medical representatives, legal and compliance staff generally serve as decision-makers.

METHODOLOGY

Industries Profiled:
Biopharmaceutical; Biotech; Communications; Pharmaceutical; Manufacturing; Consumer Products; Diagnostic; Medical Device; Health Care; Clinical Research; Laboratories


Companies Profiled:
Alkermes; Allergan; ApotheCom; AstraZeneca; Bayer; Galderma; Sanofi; Sanofi Genzyme; Sanofi Pasteur; GlaxoSmithKline ; Ironwood; Medtronic; Merck; Novartis; Sandoz; Takeda Pharmaceuticals; Tillotts Pharma; Vifor Pharma; ViiV Healthcare

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.